Biology 2012, 1(3), 521-541; doi:10.3390/biology1030521
Review

Inhibitors of HIV-1 Reverse Transcriptase—Associated Ribonuclease H Activity

1 Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, 450 Technology Drive, S.414, Pittsburgh, PA 15219, USA 2 Structural Biology, University of Pittsburgh School of Medicine, 450 Technology Drive, S.414, Pittsburgh, PA 15219, USA 3 Department of Molecular Microbiology & Immunology, University of Missouri, Columbia, MO, USA
* Author to whom correspondence should be addressed.
Received: 18 August 2012; in revised form: 26 September 2012 / Accepted: 27 September 2012 / Published: 19 October 2012
(This article belongs to the Special Issue Structural and Molecular Biology of HIV)
PDF Full-text Download PDF Full-Text [656 KB, Updated Version, uploaded 23 October 2012 11:36 CEST]
The original version is still available [656 KB, uploaded 19 October 2012 16:59 CEST]
Abstract: HIV-1 enzyme reverse transcriptase (RT) is a major target for antiviral drug development, with over half of current FDA-approved therapeutics against HIV infection targeting the DNA polymerase activity of this enzyme. HIV-1 RT is a multifunctional enzyme that has RNA and DNA dependent polymerase activity, along with ribonuclease H (RNase H) activity. The latter is responsible for degradation of the viral genomic RNA template during first strand DNA synthesis to allow completion of reverse transcription and the viral dsDNA. While the RNase H activity of RT has been shown to be essential for virus infectivity, all currently used drugs directed at RT inhibit the polymerase activity of the enzyme; none target RNase H. In the last decade, the increasing prevalence of HIV variants resistant to clinically used antiretrovirals has stimulated the search for inhibitors directed at stages of HIV replication different than those targeted by current drugs. HIV RNase H is one such novel target and, over the past few years, significant progress has been made in identifying and characterizing new RNase H inhibitor pharmacophores. In this review we focus mainly on the most potent low micromolar potency compounds, as these provide logical bases for further development. We also discuss why HIV RNase H has been a difficult target for antiretroviral drug development.
Keywords: HIV-1; reverse transcription; ribonuclease H (RNase H); ribonuclease H inhibitor (RNHI)

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Ilina, T.; LaBarge, K.; Sarafianos, S.G.; Ishima, R.; Parniak, M.A. Inhibitors of HIV-1 Reverse Transcriptase—Associated Ribonuclease H Activity. Biology 2012, 1, 521-541.

AMA Style

Ilina T, LaBarge K, Sarafianos SG, Ishima R, Parniak MA. Inhibitors of HIV-1 Reverse Transcriptase—Associated Ribonuclease H Activity. Biology. 2012; 1(3):521-541.

Chicago/Turabian Style

Ilina, Tatiana; LaBarge, Krystal; Sarafianos, Stefan G.; Ishima, Rieko; Parniak, Michael A. 2012. "Inhibitors of HIV-1 Reverse Transcriptase—Associated Ribonuclease H Activity." Biology 1, no. 3: 521-541.

Biology EISSN 2079-7737 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert